Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Relay Therapeutics (RLAY) Equity Average: 2020-2025

Historic Equity Average for Relay Therapeutics (RLAY) over the last 6 years, with Sep 2025 value amounting to $636.7 million.

  • Relay Therapeutics' Equity Average fell 16.26% to $636.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $636.7 million, marking a year-over-year decrease of 16.26%. This contributed to the annual value of $764.9 million for FY2024, which is 10.13% down from last year.
  • Relay Therapeutics' Equity Average amounted to $636.7 million in Q3 2025, which was down 8.18% from $693.4 million recorded in Q2 2025.
  • In the past 5 years, Relay Therapeutics' Equity Average registered a high of $975.0 million during Q4 2022, and its lowest value of $594.8 million during Q3 2021.
  • For the 3-year period, Relay Therapeutics' Equity Average averaged around $766.7 million, with its median value being $760.3 million (2024).
  • Its Equity Average has fluctuated over the past 5 years, first spiked by 415.92% in 2021, then declined by 21.52% in 2023.
  • Over the past 5 years, Relay Therapeutics' Equity Average (Quarterly) stood at $734.4 million in 2021, then surged by 32.75% to $975.0 million in 2022, then declined by 21.52% to $765.2 million in 2023, then climbed by 5.64% to $808.3 million in 2024, then declined by 16.26% to $636.7 million in 2025.
  • Its last three reported values are $636.7 million in Q3 2025, $693.4 million for Q2 2025, and $749.4 million during Q1 2025.